Our monthly newsletter reports on the patent law developments in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month’s issue covers relevant news from March 2020, including:
- The Federal Circuit reverses two district court decisions holding method of treatment and method of preparing claims patent ineligible
- The Federal Circuit finds that clearly limiting statements during prosecution did not create prosecution history estoppel when the PTO rejected those prosecution arguments
- A district court denies JMOL and upholds a US $752 million jury award and a 27% running royalty
